Related Experiment Video
Updated: Jun 26, 2026
06:25
Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
Published on: March 29, 2024
The insulin-like growth factor system and sarcomas
Bart Rikhof1, Steven de Jong, Albert J H Suurmeijer
1Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, The Netherlands. b.rikhof@int.umcg.nl
The Journal of Pathology
|January 17, 2009
Summary
The insulin-like growth factor (IGF) signalling system plays a key role in sarcoma development. Therapies targeting IGF signalling show promise, with early clinical trials demonstrating positive responses in Ewing
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Sarcomas are malignant mesenchymal tumors originating from bone and soft tissues.
- Identifying critical cellular signaling pathways is crucial for developing targeted sarcoma therapies.
Purpose of the Study:
- To review experimental and clinical evidence on the role of the insulin-like growth factor (IGF) signaling system in sarcoma.
- To evaluate the IGF system as a potential therapeutic target for various sarcoma types.
Main Methods:
- Review of preclinical data and clinical studies.
- Analysis of therapies targeting the IGF signaling pathway, including monoclonal antibodies against IGF receptor type 1 (IGF-1R).
Main Results:
- The IGF signaling system is implicated in the cellular transformation and progression of multiple sarcomas (rhabdomyosarcoma, synovial sarcoma, leiomyosarcoma, Ewing's sarcoma, osteosarcoma).
- Preclinical data support the IGF system as a promising therapeutic target.
- Phase 1 clinical studies using anti-IGF-1R antibodies showed objective tumor responses in Ewing's sarcoma patients.
Conclusions:
- The IGF signaling pathway is a significant factor in sarcoma pathogenesis and progression.
- Targeting the IGF system, particularly via IGF-1R inhibition, represents a viable therapeutic strategy for sarcomas.
- Further clinical investigation of IGF-targeting therapies in Ewing's sarcoma and other sarcoma subtypes is warranted.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...